欧林生物股价涨5.46%，华富基金旗下1只基金重仓，持有60万股浮盈赚取76.2万元

Group 1 - The core point of the news is the performance and market position of Olin Bio, which saw a stock price increase of 5.46% to 24.52 CNY per share, with a total market capitalization of 9.953 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine (90.99%) [1] - The company has a diverse product portfolio, including A group and C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae conjugate vaccine (3.99%), and others [1] Group 2 - Huafu Fund has a significant holding in Olin Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 600,000 shares, representing 7.56% of the fund's net value [2] - The fund has achieved a year-to-date return of 33.75% and ranks 1847 out of 8134 in its category [2] - The fund manager, Liao Qingyang, has been in charge for 4 years and 18 days, with a total fund asset size of 216 million CNY [3]